Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Methods for manipulating phagocytosis mediated by CD47
US9399682B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9399682-B2 |
| Application number | US-201514800474-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 15, 2015 |
| Priority date | Jan 15, 2008 |
| Publication date | Jul 26, 2016 |
| Grant date | Jul 26, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a human subject with a leukemia or lymphoma, the method comprising: administering to a human subject in need thereof an antibody that disrupts the binding of CD47 with SIRPα, at a dose that achieves a depletion in leukemia or lymphoma cells by increasing phagocytosis of the leukemia or lymphoma cells. 2. The method of claim 1 , wherein the leukemia is an acute leukemia. 3. The method of claim 2 , wherein the acute leukemia is ALL (acute lymphoblastic leukemia). 4. The method of claim 1 , wherein the leukemia is chronic myelogenous leukemia (CML). 5. The method of claim 1 , wherein the lymphoma is DLBCL (diffuse large B-cell lymphoma). 6. The method of claim 1 , wherein the antibody that prevents the binding of CD47 with SIRPα specifically binds to CD47. 7. The method of claim 6 , wherein the antibody is a bispecific antibody, or is administered with a second monoclonal antibody directed against a specific cancer cell marker for depletion of cells expressing the marker.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
specific for leukemia · CPC title
Drugs for disorders of the nervous system · CPC title
Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9399682B2 cover?
- Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
- Who is the assignee on this patent?
- Univ Leland Stanford Junior
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).